FY23 Revenue at Rs 11,550 Cr, Up 38%; EBITDA at Rs 2,888 Cr …

May 23, 2023 · grew 38% to Rs 11,550 crore, EBITDA was at Rs 2,888 Crore, reporting a 32% growth. Revenue growth was led by Biosimilars at 61%, Research Services at 23% and …

CouponFollow Extension

38%
OFF

FY23 Revenue At Rs 11,550 Cr, Up 38%; EBITDA At Rs 2,888 Cr …

2 weeks from now

May 23, 2023 · grew 38% to Rs 11,550 crore, EBITDA was at Rs 2,888 Crore, reporting a 32% growth. Revenue growth was led by Biosimilars at 61%, Research Services at 23% and …

biocon.com

38%
OFF

Biocon Closes FY22-23 At Rs 11,550 Cr, Up By 38%

2 weeks from now

Revenues grew 38% to Rs 11,550 crore, EBITDA was at Rs 2,888 crore, reporting a 32% growth. Revenue growth was led by Biosimilars at 61%, Research Services at 23% and Generics at …

biospectrumindia.com

59%
OFF

Biocon Q4FY23 Revenue At Rs 3,929 Cr, Up 59%, Biosimilars Up …

2 weeks from now

May 24, 2023 · BIOCON GROUP 'FY23 has been a transformational year led by the acquisition of our partnered biosimilars business from Viatris, which has significantly contributed to Biocon's …

marketscreener.com

38%
OFF

Biocon - #Biocon Reported #FY23 Revenue Of ₹ 11,550 Cr,.

2 weeks from now

#Biocon reported #FY23 revenue of ₹ 11,550 Cr, reflecting a strong 38% increase. EBITDA stood at ₹2,888 Cr, marking a robust growth of 32%. Net Profit (before exceptional items) reached …

facebook.com

38%
OFF

Biocon Closes FY22-23 At Rs 11,550 Cr, Up By 38%

2 weeks from now

May 24, 2023 · Revenues grew 38% to Rs 11,550 crore, EBITDA was at Rs 2,888 crore, reporting a 32% growth. Revenue growth was led by Biosimilars at 61%, Research Services at 23% and …

biospectrumindia.com

5%
OFF

Snapdeal Records Rs 384 Cr Revenue In FY24, Adjusted EBITDA Loss …

2 weeks from now

Dec 29, 2024 · Advertisement & promotional costs were also reduced by 23.5% to Rs 70.37 crore during the same period. Overall, the Gurugram-based firm’s total expenditure dropped by …

entrackr.com

23%
OFF

Biocon Q2FY23 Revenue At Rs 2,384 Cr, Up 23%; Core EBITDA …

2 weeks from now

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52% Biosimilars Up 34%; Research Services Up 26%; …

biocon.com

59%
OFF

Biocon Revenue Up 59% At Rs 3,929 Crore In Q4FY23

2 weeks from now

May 24, 2023 · The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%

biovoicenews.com

45%
OFF

Snapdeal Group: FY23 Revenue Rs 388 Cr, 45% Fewer Losses

2 weeks from now

Jan 1, 2024 · On a standalone basis, marketing and business promotion now account for only 31.3% of revenue in FY 2022‐23, a substantial decrease from the 66.6% reported in FY 2021 …

startuparticle.com

59%
OFF

Biocon Q4FY23 Revenue At Rs 3,929 Cr, Up 59%; Biosimilars Up …

2 weeks from now

FY23 Revenue at Rs 11,550 Cr, Up 38%; EBITDA at Rs 2,888 Cr, Up 32% ... Revenues grew 38% to Rs 11,550 crore, EBITDA was at Rs 2,888 Crore, reporting a 32% growth. Revenue …

biocon.com

87%
OFF

NoBroker In FY23: Op Revenue Grows 87% To Rs 609 Cr; Losses Up …

2 weeks from now

Jul 1, 2024 · Subsequently, losses went up by 63.8% to Rs 506 crore in FY23, up from Rs 309 crore in FY22. Its ROCE and EBITDA margins were recorded at -34% and -69.5%, …

entrackr.com

45%
OFF

Snapdeal Logs Rs 388 Cr Revenue In FY23, Reduces Losses By 45%

2 weeks from now

Dec 30, 2023 · Snapdeal cut its adjusted EBITDA loss by 65.6 per cent to Rs 144 crore in FY23, reports Entrackr. “Snapdeal’s improved performance was underpinned by its success in …

dtnext.in

35%
OFF

PRESS RELEASE Biocon Q4FY24 Revenue At Rs 3,966 Cr, …

2 weeks from now

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr FY24 Revenue at Rs 15,621 Cr, Up 35%; EBITDA at Rs 4,164 Cr, Up …

biocon.com

23%
OFF

Biocon Q2FY23 Revenue At Rs 2,384 Cr, Up 23%; Core EBITDA At …

2 weeks from now

Nov 14, 2022 · Core EBITDA was up by 34% at Rs 816 Crore, representing healthy core operating margins of 35% versus 33% in the same quarter last year. “We have delivered a …

biocon.com

FAQs about FY23 Revenue at Rs 11,550 Cr, Up 38%; EBITDA at Rs 2,888 Cr … Coupon?

How did R&D investments drive revenue growth in FY23?

Revenue growth was led by Biosimilars at 61%, Research Services at 23% and Generics at 13%. R&D Investments have nearly doubled to Rs 1,119 crore, as we seek to drive future growth. “We ended FY23 with a strong Q4 performance where Revenues grew by 59% to Rs 3,929 crore and EBITDA by 75% to Rs 1,152 crore. ...

Which countries made the most revenue in FY23?

Additionally, it also made Rs 455 crore via interest and gains on financial assets in FY23 which took its overall revenue to Rs 9,158.9 crore. Geography-wise, North America is on top with Rs 3,988.8 crore revenue followed by Europe, Asia and Latin America with Rs 1,952.5 crore, Rs 2,283.5 crore and Rs 121.8 crore, respectively. ...

How did the chemical business perform in FY23?

The revenue for the Chemicals Business was at Rs. 2,397 Cr. down 7 per cent QoQ and EBITDA stood at Rs. 368 Cr. down 25 per cent QoQ as the ECU was sequentially down by 10 per cent to Rs. 42,136 Per MT. For FY23 the revenue contribution stood at 17 per cent and 23 per cent for Chlorine Derivatives and Speciality Chemicals respectively. ...

What are Grasim Industries' financial results for FY23?

Standalone: Highest ever Revenue at Rs. 26,840 Cr. Chemicals: Highest ever Revenue and EBITDA of Rs. 10,422 Cr. and Rs. 2,271 Cr. Grasim Industries Limited today announced its Financial Results for the quarter and year ended 31st March 2023. Consolidated revenue for FY23 crossed a historic milestone of Rs. 1 Lakh Cr. reaching Rs. 1,17,627 Cr. ...

How was q2fy23 revenue compared to q2fy22?

Q2FY23 revenue at Rs 623 Crore, up 18% (YoY) from Rs 530 Crore in Q2FY22. During the quarter we launched two important products Sitagliptin and Vildagliptin in the EU, enabled by the brownfield capacity expansions undertaken at our Bengaluru and Visakhapatnam facilities. The Company also received five product approvals across markets. ...

How did Snapdeal's revenue increase in fy24?

Snapdeal’s revenue from operations increased by 2.1%, rising to Rs 379.76 crore in FY24 from Rs 371.96 crore in FY23, according to its consolidated financial statements filed with the RoC. Snapdeal’s primary revenue streams include marketing services, e-commerce enablement, and other ancillary sources. ...